longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Dr Reddys Laboratories

RDY

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 28.32, above the reasonable range, cheaper than 10.89% of the time in the past 5 years, and the industry ranks 44/255, the industry Median -1.27.

28.32xP/E
$12.25Stock price
$0.43Earnings per share
28.32xP/E
Stock price$12.25Earnings per share$0.43

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
19.49x
Typical range
17.73x–23.92x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
JNJUSJohnson & Johnson
29.33x18.50%$617.01B
RHHVFUSROCHE HOLDINGS AG
23.55x--$364.13B
RHHBYUSRoche
21.54x--$333.05B
NVSUSNOVARTIS AG
21.01x1.82%$268.00B
AZNUSAstraZeneca
23.30x--$243.34B
SNYUSSanofi
20.82x20.80%$95.65B
SNYNFUSSanofi
20.65x--$94.88B
MKKGYUSMerck
24.39x--$67.11B
CHGCYUSChugai Pharmaceutical
20.85x--$62.78B
RDYUSDr Reddys Laboratories
28.32x11.22%$10.20B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.